- Home
- NCPL vs CMND Comparison
NCPL vs CMND Comparison
Compare NCPL & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- CMND
- Stock Information
- Founded
- NCPL 1984
- CMND 2017
- Country
- NCPL United States
- CMND Canada
- Employees
- NCPL N/A
- CMND N/A
- Industry
- NCPL Investment Managers
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- CMND Health Care
- Exchange
- NCPL Nasdaq
- CMND Nasdaq
- Market Cap
- NCPL 4.3M
- CMND 4.8M
- IPO Year
- NCPL N/A
- CMND N/A
- Fundamental
- Price
- NCPL $6.50
- CMND $0.97
- Analyst Decision
- NCPL
- CMND
- Analyst Count
- NCPL 0
- CMND 0
- Target Price
- NCPL N/A
- CMND N/A
- AVG Volume (30 Days)
- NCPL 907.7K
- CMND 2.2M
- Earning Date
- NCPL 07-28-2025
- CMND 06-12-2025
- Dividend Yield
- NCPL N/A
- CMND N/A
- EPS Growth
- NCPL N/A
- CMND N/A
- EPS
- NCPL N/A
- CMND N/A
- Revenue
- NCPL $812,612.00
- CMND N/A
- Revenue This Year
- NCPL N/A
- CMND N/A
- Revenue Next Year
- NCPL $101.16
- CMND N/A
- P/E Ratio
- NCPL N/A
- CMND N/A
- Revenue Growth
- NCPL N/A
- CMND N/A
- 52 Week Low
- NCPL $1.41
- CMND $0.80
- 52 Week High
- NCPL $11.90
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- NCPL 62.33
- CMND 54.57
- Support Level
- NCPL $5.25
- CMND $0.85
- Resistance Level
- NCPL $7.31
- CMND $1.31
- Average True Range (ATR)
- NCPL 1.16
- CMND 0.08
- MACD
- NCPL 0.20
- CMND 0.02
- Stochastic Oscillator
- NCPL 60.04
- CMND 33.60
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.